Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
1984.
Parkinson's Disease, 1984.
The Lancet,
Vol. 323,
Issue. 8381,
p.
829.
Calne, Donald B.
1984.
Progress in Parkinson's Disease.
New England Journal of Medicine,
Vol. 310,
Issue. 8,
p.
523.
Eadie, Mervyn J.
and
Smith, Anthony J.
1985.
Problems in the contemporary treatment of parkinsonism.
Medical Journal of Australia,
Vol. 142,
Issue. 2,
p.
113.
Friedman, Andrzej
1985.
Levodopa-induced dyskinesia: clinical observations.
Journal of Neurology,
Vol. 232,
Issue. 1,
p.
29.
Markham, Charles H.
and
Diamond, Shirley G.
1986.
Long‐term follow‐up of early dopa treatment in Parkinson's disease.
Annals of Neurology,
Vol. 19,
Issue. 4,
p.
365.
Calne, Donald B.
and
Rinne, Urpo K.
1986.
Controversies in the management of Parkinson's disease.
Movement Disorders,
Vol. 1,
Issue. 3,
p.
159.
Pall, H. S.
Williams, A. C.
and
Ramsden, D. B.
1986.
THERAPEUTIC PROGRESS—REVIEW XX DRUG TREATMENT OF PARKINSON'S DISEASE.
Journal of Clinical Pharmacy and Therapeutics,
Vol. 11,
Issue. 4,
p.
229.
Feldman, Robert G.
Kaye, Jeffrey A.
and
Lannon, Margaret C.
1986.
Parkinson's Disease: Follow‐up After “Drug Holiday”.
The Journal of Clinical Pharmacology,
Vol. 26,
Issue. 8,
p.
662.
Diamond, Shirley G.
Marchkham, Charles H.
Hoehn, Marchgaret M.
McDowell, Fletcher H.
and
Muenter, Manfred D.
1987.
Multi‐center study of Parkinson mortality with early versus later dopa treatment.
Annals of Neurology,
Vol. 22,
Issue. 1,
p.
8.
Gauthier, S.
and
Gauthier, L.
1987.
Current Status of Levodopa Therapy in Idiopathic Parkinson's Disease.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques,
Vol. 14,
Issue. S3,
p.
452.
Duvoisin, Roger C.
1987.
To treat early or to treat late?.
Annals of Neurology,
Vol. 22,
Issue. 1,
p.
2.
Lang, Anthony E.
1987.
Manipulating the dopaminergic system in Parkinson's disease.
Pharmacology & Therapeutics,
Vol. 32,
Issue. 1,
p.
51.
Riopelle, Richard J.
1987.
Bromocriptine and the Clinical Spectrum of Parkinson's Disease.
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques,
Vol. 14,
Issue. S3,
p.
455.
Lataste, X.
and
Findley, L. J.
1988.
Methods in Clinical Trials in Neurology.
p.
223.
Jansen, Ernst N.H.
and
Meerwaldt, Jan D.
1988.
Madopar HBS in Parkinson patients with nocturnal akinesia.
Clinical Neurology and Neurosurgery,
Vol. 90,
Issue. 1,
p.
35.
LeWitt, P. A.
1989.
Drugs for the Treatment of Parkinson’s Disease.
Vol. 88,
Issue. ,
p.
325.
Horstink, M. W. I. M.
Zijlmans, J. C. M.
Pasman, J. W.
Berger, H. J. C.
Korten, J. J.
and
Van 't Hof, M. A.
1990.
Which risk factors predict the levodopa response in fluctuating Parkinson's disease?.
Annals of Neurology,
Vol. 27,
Issue. 5,
p.
537.
Fischer, P. A.
1992.
Neuro-Psychopharmaka.
p.
3.
Fischer, P.-A.
1993.
Inhibitors of Monoamine Oxidase B.
p.
51.
Durso, R
Isaac, K
Perry, L
Saint-Hilaire, M
and
Feldman, R G
1993.
Age influences magnitude but not duration of response to levodopa..
Journal of Neurology, Neurosurgery & Psychiatry,
Vol. 56,
Issue. 1,
p.
65.